A poke in the eye.
Gurney
Margaret
M
D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017277:Drug Approval; D016527:Drug Costs; D006801:Humans; D008268:Macular Degeneration / Q000453:epidemiology / Q000628:therapy*; D024802:Nurse's Role; D009885:Ophthalmology / Q000458:organization & administration; D010818:Practice Patterns, Physicians' / Q000458:organization & administration; D000069579:Ranibizumab; D006113:United Kingdom / Q000453:epidemiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab